title: Rare presentation of secondary cutaneous involvement by splenic marginal zone lymphoma: report of a case and review of the literature.
abstract: Cutaneous lymphomas encompass a broad spectrum of malignancies, including both primary and secondary cutaneous lymphomas. Determining the exact subtype of cutaneous lymphoma offers prognostic importance and directs therapeutic decisions. We describe the case of a 67-year-old woman with cutaneous involvement of splenic marginal zone lymphoma successfully treated with rituximab and bendamustine. We discuss the diagnostic work-up, including the histopathologic findings and treatment of this disease.
authors.affiliation: *Harvard Medical School, Boston, MA; Departments of †Pathology, ‡Medicine, Division of Hematology-Oncology, and §Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
authors.forename: Jeffrey M
authors.initials: JM
authors.lastname: Cohen
authors.forename: Rosalynn M
authors.initials: RM
authors.lastname: Nazarian
authors.forename: Judith A
authors.initials: JA
authors.lastname: Ferry
authors.forename: Ronald W
authors.initials: RW
authors.lastname: Takvorian
authors.forename: Joi B
authors.initials: JB
authors.lastname: Carter
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000069461:Bendamustine Hydrochloride; D014408:Biomarkers, Tumor / Q000032:analysis; D001706:Biopsy; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D018442:Lymphoma, B-Cell, Marginal Zone / Q000737:chemistry / Q000188:drug therapy / Q000473:pathology*; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage; D011237:Predictive Value of Tests; D012074:Remission Induction; D000069283:Rituximab; D012878:Skin Neoplasms / Q000737:chemistry / Q000188:drug therapy / Q000556:secondary*; D013160:Splenic Neoplasms / Q000737:chemistry / Q000188:drug therapy / Q000473:pathology*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D014408:Biomarkers, Tumor; D009588:Nitrogen Mustard Compounds; D000069283:Rituximab; D000069461:Bendamustine Hydrochloride